ERBB2 and cancer: Among all breast cancer subtypes, the triple-negative type is more likely to recur, and shows the lowest 5-year survival rate (85% for nonmetastatic triple negative cancer, 94% for hormone-receptor-positive, and 99% for ERBB2-positive cancer).